Tag: In.Pact
Cost effectiveness of urea-based DCB treatment for CLTI patients “extremely important”
A range of experts, including Koen Deloose (Dendermonde, Belgium), Thomas Zeller (Bad Krozingen, Germany), Marianne Brodmann (Graz, Austria) and Antonio Micari (Messina, Italy), talk...
Experts react to “compelling” 36-month IN.PACT AV Access trial data
NOTE: This video is ONLY available to watch in selected countries and geographies
Robert Shahverdyan (Hamburg, Germany), Matteo Tozzi (Varese, Italy), Alexandros Mallios (Paris,...
Roundtable: Will latest IN.PACT AV Access data impact practice and can...
NOTE: This video is ONLY available to watch in selected countries and geographies
In this Vascular News roundtable, Andrew Holden (moderator; Auckland, New Zealand) is joined...
Medtronic gains FDA approval for IN.PACT 018 DCB
Medtronic has announced approval from the US Food and Drug Administration (FDA) for the IN.PACT 018 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter, a...
First time data release: View the full IN.PACT AV Access trial...
NOTE: This video is ONLY available to watch in selected countries and geographies
In a late-breaking Podium 1st presentation at the 2022 Charing Cross...
Medtronic issues voluntary recall for subset of IN.PACT Admiral and IN.PACT...
Medtronic recently voluntarily recalled a subset of its IN.PACT Admiral and IN.PACT AV paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheters due to the potential...
Episode 4: Real world data show IN.PACT Admiral DCB is “very...
In this penultimate episode of a special five-part series on the history of drug-coated balloons (DCBs), Jos van den Berg (Lugano, Switzerland) is joined...
VIVA 2021: IN.PACT Admiral DCB found to provide “high five-year freedom...
Real-world data drawn from the IN.PACT Global study looking at five-year freedom from clinically-driven target lesion revascularisation (TLR) among prespecified chronic total occlusion (CTO),...
More mixed results for DCBs in AV access maintenance as evidence...
Additional randomised controlled data regarding the effectiveness of drug-coated balloons (DCBs) in maintaining arteriovenous (AV) access offers new evidence, but it is freighted with...
Episode 2: Are all peripheral drug-coated balloons created equal?
“Not all Drug-Coated Balloons (DCBs) are created equal”, Juan Granada (New York, USA), tells Vascular News in this second episode of a four-part series on the history of DCBs.
Granada discusses why there...
Trialists’ insights on the 2-year results from the COMPARE trial
NOTE: This video is ONLY available to watch in selected countries and geographies
Sabine Steiner (Leipzig, Germany) sits down with Michael Jaff, the CMO...
‘Indisputable evidence’ that DCB is the “gold standard” for treating vascular...
NOTE: This video is ONLY available to watch in selected countries and geographies
Tobias Steinke (Düsseldorf, Germany), Matteo Tozzi (Varese, Italy) and Robert Shahverdyan...
IN.PACT™ AV Access trial shows improvement in patency “for the entire...
A trio of vascular experts including Raphaël Coscas (Paris, France), Alexandros Mallios (Paris, France) and Kate Steiner (Stevenage, UK) discuss the key findings of...
New England Journal Of Medicine publishes “outstanding” six-month IN.PACT AV Access™...
NOTE: This video is ONLY available to watch in selected countries and geographies
Robert Lookstein (New York, USA; principal investigator) and Andrew Holden (Auckland,...
Endovascular late-breaking trials presented at TCT 2020
Findings from a series of late-breaking trials in the endovascular field were presented recently at TCT Connect (14–18 October, virtual), the 32nd annual scientific...
Impressions from LINC 2020: Strong clinical and economic case for widespread...
NOTE: This video is ONLY available to watch in selected countries and geographies
Andrew Holden (Auckland, New Zealand), Alexandros Mallios (Paris, France), Robert Lookstein (New...
LINC 2020: High- and low-dose paclitaxel-coated balloons exhibit comparable results at...
At the 2020 Leipzig Interventional Course (28–31 January, Leipzig, Germany), Sabine Steiner (University of Leipzig, Leipzig, Germany) presented one-year results of the COMPARE-RTC of...
A panel of experts comments on IN.PACT AV ACCESS data
NOTE: This video is ONLY available to watch in selected countries and geographies
Jos van den Berg (Lugano, Switzerland) speaks to Andrew Holden (Auckland, New...
Webinar: Safety of paclitaxel devices – what does the evidence say?
Jos van den Berg (Lugano, Switzerland), Antonio Micari (Bergamo, Italy) and Marianne Brodmann (Graz, Austria) sit down after a specially convened US FDA panel...
Patient-level analysis shows no correlation between paclitaxel and mortality—reactions from LINC
Renowned experts expressed confidence in the continued use of paclitaxel-coated devices after independent patient-level data presented at LINC 2019 did not show correlation between...
Three-year Japanese results show IN.PACT Admiral DCB offers “consistent and durable”...
The IN.PACT Admiral drug-coated balloon (DCB; Medtronic) exhibits a consistent and durable treatment effect in “a more complex patient demographic than typically seen in...
IN.PACT Admiral DCB receives FDA approval for long SFA lesions
Medtronic has announced that it has received US Food and Drug Administration (FDA) approval for the IN.PACT Admiral drug-coated balloon (DCB) to treat long superficial...
Latest data on Lutonix and IN.PACT drug-coated balloons in AV access...
There in an increasing physician interest in exploring the role of drug-coated balloons in arteriovenous (AV) access. At the Leipzig Interventional Course (LINC; 30...
First data from head-to-head comparison of Ranger and IN.PACT drug-coated balloons...
Early data from the first randomised controlled trial to compare two drug-coated balloons (DCBs) suggest that the primary patency obtained with the Ranger DCB...
LINC 2018 data highlight IN.PACT Admiral as safe and effective treatment...
Medtronic added to its robust body of clinical evidence supporting the IN.PACT Admiral drug-coated balloon with new presentations that demonstrated durable and consistent clinical...
Results from Asia and Belgium demonstrate consistent results from Medtronic In.Pact...
New data presented at the 2017 Leipzig Interventional Course (LINC) have demonstrated strong efficacy and consistent outcomes for Medtronic’s In.Pact Admiral drug-coated balloon across...
